Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

NCT02810418 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Neoplasms
Pancreatic Neoplasms

Interventions

DRUG: LMB-100
DRUG: Nab-Paclitaxel
DEVICE: Mesothelin Expression
DRUG: LMB-100

Sponsor

National Cancer Institute (NCI)